Cardiol Therapeutics Inc (CRDL)

Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDTJune 23, 2026 7:27 AM
PR Newswire (Canada) TORONTO, June 23, 2026 /CNW/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, announces that the Company's virtual Annual General Meeting of Shareholders (the "AGM") will be webcast on June 24, 2026, at 4:30 p.m. EDT. Cardiol Therapeutics' 2026 AGMWhen: June 24, 2026, at 4:30 p.m. EDT
Where: Virtual meeting only via live webcast online at: meetings.lumiconnect.com/400-405-294-535Additional information about the AGM, including details on how to participate and vote, is available on the Company's website at cardiolrx.com/investors/events-presentations/.About Cardiol TherapeuticsCardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company's lead small-molecule drug candidate, CardiolRx™, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.The MAVERIC Program is evaluating CardiolRx™ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations. The program comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing pivotal Phase III MAVERIC trial (NCT06708299). The U.S. FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis, including recurrent pericarditis.The ARCHER Program also studied CardiolRx™ in acute myocarditis—an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in individuals under 35 years of age. The program comprises the completed Phase II ARCHER study (NCT05180240), which evaluated the safety, tolerability, and efficacy of CardiolRx™ in this patient population.The Company is also developing CRD-38, a novel, subcutaneously administered drug formulation intended for the treatment of inflammatory heart disease, including heart failure—a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding US$30 billion per year.For more information about Cardiol Therapeutics, please visit cardiolrx.com.Cautionary statement regarding forward-looking information:
This news release contains "forward-looking information" within the meaning of applicable securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol believes, expects, or anticipates will, may, could, or might occur in the future are "forward-looking information". Forward looking information contained herein may include, but is not limited to statements regarding the Company's focus on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease; the Company's intended clinical studies and trial activities and timelines associated with such activities, including the Company's plan to complete the Phase III study in recurrent pericarditis with CardiolRx™; the Company's plan to advance the development of CRD-38, a novel subcutaneous formulation intended for the treatment of inflammatory heart disease, including heart failure, including through the initiation of a Phase I clinical program; and the Company's ability to address its strategic priorities. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is based on certain assumptions and is also subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward looking information, and are not (and should not be considered to be) guarantees of future performance. These risks and uncertainties and other factors include the risks and uncertainties referred to in the Company's Annual Information Form filed with the Canadian securities administrators and U.S. Securities and Exchange Commission on March 31, 2026, available on SEDAR+ at sedarplus.ca and EDGAR at sec.gov, as well as the risks and uncertainties associated with product commercialization and clinical studies. These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information, and such information may not be appropriate for other purposes. Any forward-looking information speaks only as of the date of this press release and, except as may be required by applicable securities laws, Cardiol disclaims any intent or obligation to update or revise such forward-looking information, whether as a result of new information, future events, or results, or otherwise. Investors are cautioned not to rely on these forward-looking statements. View original content to download multimedia:https://www.prnewswire.com/news-releases/cardiol-therapeutics-to-webcast-virtual-annual-general-meeting-of-shareholders-on-june-24th-at-430-pm-edt-302807049.htmlSOURCE Cardiol Therapeutics Inc. Original: Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT

A real Phase III in progress, with positive published Phase II data in a related indication. Recurrent pericarditis is a genuine unmet need. Patent protection extends to roughly 2040, and the board was recently strengthened with a former Eli Lilly chief medical officer.

Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQMay 14, 2026 7:27 AM
PR Newswire (Canada) TORONTO, May 14, 2026 /CNW/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate in a Fireside Chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ in New York, NY, on May 19, 2026, at 1:30 p.m. EDT. A live webcast of the Fireside Chat will be accessible under "Events & Presentations" in the Investors section of the Cardiol website (www.cardiolrx.com/investors/events-presentations/). The replay will be available for 90 days following the conference.About Cardiol TherapeuticsCardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company's lead small-molecule drug candidate, CardiolRx™, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.The MAVERIC Program is evaluating CardiolRx™ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations. The program comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing pivotal Phase III MAVERIC trial (NCT06708299). The U.S. FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis, including recurrent pericarditis.The ARCHER Program also studied CardiolRx™, specifically in acute myocarditis—an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in individuals under 35 years of age. The program comprises the completed Phase II ARCHER study (NCT05180240), which evaluated the safety, tolerability, and efficacy of CardiolRx™ in this patient population.The Company is also developing CRD-38, a novel, subcutaneously administered drug formulation intended for the treatment of inflammatory heart disease, including heart failure—a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding US$30 billion per year.For more information about Cardiol Therapeutics, please visit cardiolrx.com.Cautionary statement regarding forward-looking information:This news release contains "forward-looking information" within the meaning of applicable securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol believes, expects, or anticipates will, may, could, or might occur in the future are "forward-looking information". Forward looking information contained herein may include, but is not limited to statements regarding the Company's focus on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease; the Company's intended clinical studies and trial activities and timelines associated with such activities, including the Company's plan to complete the Phase III study in recurrent pericarditis with CardiolRx™; the Company's plan to advance the development of CRD-38, a novel subcutaneous formulation intended for the treatment of inflammatory heart disease, including heart failure. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is based on certain assumptions and is also subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward looking information, and are not (and should not be considered to be) guarantees of future performance. These risks and uncertainties and other factors include the risks and uncertainties referred to in the Company's Annual Information Form filed with the Canadian securities administrators and U.S. Securities and Exchange Commission (as part of its Annual Report on Form 40-F) on March 31, 2026, available on SEDAR+ at sedarplus.ca and EDGAR at sec.gov, as well as the risks and uncertainties associated with product commercialization and clinical studies. These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information, and such information may not be appropriate for other purposes. Any forward-looking information speaks only as of the date of this press release and, except as may be required by applicable securities laws, Cardiol disclaims any intent or obligation to update or revise such forward-looking information, whether as a result of new information, future events, or results, or otherwise. Investors are cautioned not to rely on these forward-looking statements. View original content to download multimedia:https://www.prnewswire.com/news-releases/cardiol-therapeutics-to-participate-in-fireside-chat-at-hc-wainwright-4th-annual-bioconnect-investor-conference-at-the-nasdaq-302772040.htmlSOURCE Cardiol Therapeutics Inc. Original: Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ

$CRDL "The upcoming publication provides important independent validation of the clinical findings generated in our Phase II MAvERIC study and further supports the potential of CardiolRx™ as a differentiated, non-immunosuppressive therapy for recurrent pericarditis," said David Elsley, President and Chief Executive Officer of Cardiol Therapeutics. "Publication in the Journal of the American Heart Association underscores the clinical relevance of the observed reductions in pericarditis pain and inflammation, together with the favorable safety and tolerability profile demonstrated in this patient population. We believe these data strengthen the foundation for MAVERIC and reinforce the broader opportunity for CardiolRx™ to address a significant unmet medical need in recurrent pericarditis."

The Phase II MAvERIC results published in JAHA represent another important step in advancing clinical understanding of the potential role of CardiolRx™ in the treatment of inflammation-driven heart diseases and helped inform the design and advancement of MAVERIC, a randomized, double-blind, placebo-controlled, pivotal Phase III trial evaluating CardiolRx™ for the prevention of recurrent pericarditis.

$CRDL Breaking News ! Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association
https://finance.yahoo.com/sectors/healthcare/articles/cardiol-therapeutics-phase-ii-maveric-112700976.html

$CRDL News: Cardiol Therapeutics’ Phase II MAvERIC results accepted for publication in the Journal of the American Heart Association. Findings indicate CardiolRx™ may change the treatment landscape for recurrent pericarditis and reinforce the Phase III program (now >75% enrolled).

Read more: https://wix.to/pqhQbSI

#CRDL #Cardiology #ClinicalTrials #Pericarditis

$CRDL announced the results from our Phase II MAvERIC study evaluating CardiolRx™ in patients with recurrent pericarditis have been accepted for publication in a forthcoming issue of the Journal of the American Heart Association (@JAHA_AHA). #JAHA #ClinicalTrials @CardiolRx https://www.cardiolrx.com/cardiol-therapeutics-phase-ii-maveric-results-accepted-for-publication-in-the-journal-of-the-american-heart-association/

Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart AssociationMay 7, 2026 7:27 AM
PR Newswire (US) Results demonstrate CardiolRx™ may represent a paradigm shift in the treatment of patients with recurrent pericarditis and further validate the ongoing Phase III trial, which recently surpassed 75% enrollment.TORONTO, ON, May 7, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that the results from its Phase II study evaluating CardiolRx™ in patients with recurrent pericarditis have been accepted for publication in a forthcoming issue of the Journal of the American Heart Association ("JAHA"). The peer-reviewed publication highlights clinical findings demonstrating that treatment with CardiolRx™ was associated with rapid and sustained reductions in pericarditis pain and inflammation in patients with a high baseline disease burden. The study also reported a substantial reduction in pericarditis episodes per year and a favorable safety and tolerability profile, supporting its continued development in a Phase III program. These findings provide important clinical rationale for the ongoing pivotal Phase III MAVERIC trial ("MAVERIC"), evaluating CardiolRx™ in patients with recurrent pericarditis, which recently surpassed 75% enrollment."The upcoming publication provides important independent validation of the clinical findings generated in our Phase II MAvERIC study and further supports the potential of CardiolRx™ as a differentiated, non-immunosuppressive therapy for recurrent pericarditis," said David Elsley, President and Chief Executive Officer of Cardiol Therapeutics. "Publication in the Journal of the American Heart Association underscores the clinical relevance of the observed reductions in pericarditis pain and inflammation, together with the favorable safety and tolerability profile demonstrated in this patient population. We believe these data strengthen the foundation for MAVERIC and reinforce the broader opportunity for CardiolRx™ to address a significant unmet medical need in recurrent pericarditis."The Phase II MAvERIC results published in JAHA represent another important step in advancing clinical understanding of the potential role of CardiolRx™ in the treatment of inflammation-driven heart diseases and helped inform the design and advancement of MAVERIC, a randomized, double-blind, placebo-controlled, pivotal Phase III trial evaluating CardiolRx™ for the prevention of recurrent pericarditis.About PericarditisPericarditis refers to inflammation of the pericardium (the membrane or sac that surrounds the heart), which frequently results from a viral infection. Patients may have multiple recurrences following that initial episode, and the primary goal of treatment is recurrence prevention. Symptoms include debilitating chest pain, shortness of breath and fatigue, resulting in physical limitations, reduced quality of life, emergency department visits, and hospitalizations. Current treatment options are limited and often involve prolonged use of immunosuppressive therapies including corticosteroids and injectable biologics, which are associated with risk of significant side effects and dependency. On an annual basis, the number of patients in the United States experiencing at least one recurrence is estimated at 40,000. Approximately 60% of patients with more than one recurrence suffer for more than two years, and one third remain impacted at five years.About Cardiol TherapeuticsCardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company's lead small-molecule drug candidate, CardiolRx™, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.The MAVERIC Program is evaluating CardiolRx™ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations. The program comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing pivotal Phase III MAVERIC trial (NCT06708299). The U.S. FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis, including recurrent pericarditis.The ARCHER Program also studied CardiolRx™ in acute myocarditis—an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in individuals under 35 years of age. The program comprises the completed Phase II ARCHER study (NCT05180240), which evaluated the safety, tolerability, and efficacy of CardiolRx™ in this patient population.The Company is also developing CRD-38, a novel, subcutaneously administered drug formulation intended for the treatment of inflammatory heart disease, including heart failure—a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding US$30 billion per year.For more information about Cardiol Therapeutics, please visit cardiolrx.com.Cautionary statement regarding forward-looking information:
This news release contains "forward-looking information" within the meaning of applicable securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol believes, expects, or anticipates will, may, could, or might occur in the future are "forward-looking information". Forward looking information contained herein may include, but is not limited to statements regarding the Company's focus on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease; the Company's intended clinical studies and trial activities and timelines associated with such activities, including the Company's plan to complete the Phase III study in recurrent pericarditis with CardiolRx™; the Company's plan to advance the development of CRD-38, a novel subcutaneous formulation intended for the treatment of inflammatory heart disease, including heart failure, including through the initiation of a Phase I clinical program; the Company's belief that the upcoming publication provides important independent validation of the clinical findings generated in the Phase II MAvERIC study and further supports the potential of CardiolRx™ as a differentiated, non-immunosuppressive therapy for recurrent pericarditis, validate and provide important clinical rationale for the ongoing pivotal Phase III MAVERIC trial, reinforce the broader opportunity to improve treatment options for patients and are an important step in disseminating and advancing clinical understanding of the potential role of CardiolRx™ in the treatment of inflammation-driven heart diseases; the Company's expectation that MAVERIC will support an NDA with the U.S. FDA.; and the Company's ability to address its strategic priorities. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is based on certain assumptions and is also subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward looking information, and are not (and should not be considered to be) guarantees of future performance. These risks and uncertainties and other factors include the risks and uncertainties referred to in the Company's Annual Information Form filed with the Canadian securities administrators and U.S. Securities and Exchange Commission on March 31, 2026, available on SEDAR+ at sedarplus.ca and EDGAR at sec.gov, as well as the risks and uncertainties associated with product commercialization and clinical studies. These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information, and such information may not be appropriate for other purposes. Any forward-looking information speaks only as of the date of this press release and, except as may be required by applicable securities laws, Cardiol disclaims any intent or obligation to update or revise such forward-looking information, whether as a result of new information, future events, or results, or otherwise. Investors are cautioned not to rely on these forward-looking statements. View original content to download multimedia:https://www.prnewswire.com/news-releases/cardiol-therapeutics-phase-ii-maveric-results-accepted-for-publication-in-the-journal-of-the-american-heart-association-302765183.htmlSOURCE Cardiol Therapeutics Inc. Original: Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association

$CRDL ON ALERT! From rare disease to heart failure.

David Elsley highlights how ARCHER findings may open new directions across inflammatory heart disease, including rare disease and large-market indications. $CRDL pic.twitter.com/xGJNXlQNs9— Cardiol Therapeutics Inc. (@CardiolRx) May 1, 2026

$CRDL - Persistent inflammation can lead to irreversible damage in the heart.

David Elsley highlights Cardiol’s cardioprotective approach, designed to reduce inflammation-driven structural damage in the heart and support recovery.


Persistent inflammation can lead to irreversible damage in the heart.

David Elsley highlights Cardiol’s cardioprotective approach, designed to reduce inflammation-driven structural damage in the heart and support recovery. $CRDL pic.twitter.com/S5EfwOeyli— Cardiol Therapeutics Inc. (@CardiolRx) April 30, 2026

$CRDL Growing interest in MAVERIC is expected to support the activation of up to seven additional U.S. clinical centers, with the total number anticipated to reach 25; Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program https://finance.yahoo.com/sectors/healthcare/articles/cardiol-therapeutics-expands-u-maveric-112700641.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr @CardiolRx @Nasdaq

Ellis Martin: Cardiol Therapeutics $CRDL CEO David Elsley on Breakthrough Heart Disease Treatment

$CRDL News Cardiol Therapeutics Up In US Premarket As Expands Phase 3 Maveric Trial to Include 7 More Clinical Centers in the U.S.
: https://finance.yahoo.com/sectors/healthcare/articles/cardiol-therapeutics-us-premarket-expands-120756014.html

$CRDL Cardiol Therapeutics Inc. is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. @CardiolRx https://cardiolrx.com/about-us/#section=overview

$CRDL News! Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program
https://www.stockonhighalert.com/post/crdl-cardiol-therapeutics-expands-u-s-maveric-phase-iii-trial-network-to-address-growing-interest

Leading enrolling centers include Cleveland Clinic, three major campuses of the Mayo Clinic, Northwestern University, Massachusetts General Hospital, Columbia University–NewYork-Presbyterian, NYU Langone Health, Lenox Hill Hospital/Northwell Health, and Houston Methodist Hospital.

Growing interest in MAVERIC is expected to support the activation of up to seven additional U.S. clinical centers, with the total number anticipated to reach 25.

Patient enrollment surpassed 50% in early January and has now reached 75%.

Target recruitment is anticipated by the end of Q2 2026, with the potential to extend into Q3 to accommodate patient enrollment from the additional clinical sites.

MAVERIC builds on positive Phase II data and is expected to support a New Drug Application with the U.S. FDA.


TORONTO, April 28, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, today announced the continued expansion of its pivotal Phase III MAVERIC trial in the United States ("U.S."), with the planned activation of up to seven additional clinical centers. Patient enrollment in MAVERIC surpassed the 50% threshold in early January and has now reached 75%. Target recruitment is anticipated by the end of Q2 2026, with the potential to extend into Q3 to accommodate patient enrollment from additional clinical sites.


"Broadening the MAVERIC clinical site network reflects the strong interest we have received from leading clinical centers across the United States and underscores the level of investigator conviction in both the therapeutic rationale and the unmet need in recurrent pericarditis," said David Elsley, President and Chief Executive Officer of Cardiol Therapeutics. "The participation of multiple premier cardiovascular research institutions gives us confidence that MAVERIC will generate a robust dataset to define the clinical profile of CardiolRx™ and support its potential as a non-immunosuppressive oral, more accessible therapy earlier in the treatment pathway."



MAVERIC Phase III Trial

MAVERIC is a randomized, double-blind, placebo-controlled pivotal Phase III trial evaluating CardiolRx™ for the prevention of disease recurrence in patients with recurrent pericarditis. The study is designed to enroll approximately 110 patients. MAVERIC was designed with input from the U.S. Food and Drug Administration ("FDA"), with alignment on trial design achieved at an end-of-Phase II meeting in April 2025. The first patient was randomized at Northwestern University in April 2025.


Phase II Foundation

MAVERIC builds on the clinical evidence established in the Phase II MAvERIC study, which demonstrated that CardiolRx™ produced rapid and sustained reductions in pericarditis pain and inflammation, along with a substantial decrease in recurrent episodes per year. These findings, presented at the American Heart Association Scientific Sessions 2024, provide a compelling clinical and mechanistic foundation for the ongoing pivotal Phase III program and support the potential for CardiolRx™ to address a significant unmet need in recurrent pericarditis.


About Pericarditis

Pericarditis refers to inflammation of the pericardium (the membrane or sac that surrounds the heart), which frequently results from a viral infection. Patients may have multiple recurrences following that initial episode, and the primary goal of treatment is recurrence prevention. Symptoms include debilitating chest pain, shortness of breath and fatigue, resulting in physical limitations, reduced quality of life, emergency department visits, and hospitalizations. Significant accumulation of pericardial fluid and scarring can progress to life-threatening constriction of the heart. On an annual basis, the number of patients in the United States experiencing at least one recurrence is estimated at 40,000. Approximately 60% of patients with more than one recurrence suffer for more than two years, and one third remain impacted at five years. Hospitalization due to recurrent pericarditis is typically associated with a 6-8-day stay and cost per stay is estimated to range between $20,000 and $30,000 in the United States.



About Cardiol Therapeutics

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company's lead small-molecule drug candidate, CardiolRx™, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.


The MAVERIC Program is evaluating CardiolRx™ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations. The program comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing pivotal Phase III MAVERIC trial (NCT06708299). The U.S. FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis, including recurrent pericarditis.


The ARCHER Program also studied CardiolRx™, specifically in acute myocarditis—an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in individuals under 35 years of age. The program comprises the completed Phase II ARCHER study (NCT05180240), which evaluated the safety, tolerability, and efficacy of CardiolRx™ in this patient population.

The Company is also developing CRD-38, a novel, subcutaneously administered drug formulation intended for the treatment of inflammatory heart disease, including heart failure—a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding US$30 billion per year.

For more information about Cardiol Therapeutics, please visit cardiolrx.com.


Cautionary statement regarding forward-looking information:

This news release contains "forward-looking information" within the meaning of applicable securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol believes, expects, or anticipates will, may, could, or might occur in the future are "forward-looking information". Forward looking information contained herein may include, but is not limited to statements regarding the Company's focus on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease; the Company's intended clinical studies and trial activities and timelines associated with such activities, including the Company's plan to complete the Phase III study in recurrent pericarditis with CardiolRx™; the Company's plan to advance the development of CRD-38, a novel subcutaneous formulation intended for the treatment of inflammatory heart disease, including heart failure, including through the initiation of a Phase I clinical program; the Company's belief that results from the ARCHER trial provide compelling clinical proof of concept for CardiolRx™ and strengthen the scientific and clinical rationale for Cardiol's novel therapeutic approach for inflammatory cardiac conditions, including its lead Phase III program in recurrent pericarditis; the Company's expectation that the Phase III MAVERIC trial will reach full enrollment in Q2 2026 with the potential to extend into Q3 to accommodate patient enrollment from the additional clinical sites; the Company's planned activation of up to seven additional clinical centers; the Company's expectation that MAVERIC will support an NDA with the U.S. FDA; the Company's belief that the participation of multiple premier cardiovascular research institutions gives it confidence that MAVERIC will generate a robust dataset to define the clinical profile of CardiolRx™ and support its potential as a non-immunosuppressive oral, more accessible therapy earlier in the treatment pathway; and the Company's ability to address its strategic priorities. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is based on certain assumptions and is also subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward looking information, and are not (and should not be considered to be) guarantees of future performance. These risks and uncertainties and other factors include the risks and uncertainties referred to in the Company's Annual Information Form filed with the Canadian securities administrators and U.S. Securities and Exchange Commission on March 31, 2026, available on SEDAR+ at sedarplus.ca and EDGAR at sec.gov, as well as the risks and uncertainties associated with product commercialization and clinical studies. These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information, and such information may not be appropriate for other purposes. Any forward-looking information speaks only as of the date of this press release and, except as may be required by applicable securities laws, Cardiol disclaims any intent or obligation to update or revise such forward-looking information, whether as a result of new information, future events, or results, or otherwise. Investors are cautioned not to rely on these forward-looking statements.


SOURCE Cardiol Therapeutics Inc.

Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal ProgramApril 28, 2026 7:27 AM
PR Newswire (Canada)

Leading enrolling centers include Cleveland Clinic, three major campuses of the Mayo Clinic, Northwestern University, Massachusetts General Hospital, Columbia University–NewYork-Presbyterian, NYU Langone Health, Lenox Hill Hospital/Northwell Health, and Houston Methodist Hospital.Growing interest in MAVERIC is expected to support the activation of up to seven additional U.S. clinical centers, with the total number anticipated to reach 25.Patient enrollment surpassed 50% in early January and has now reached 75%.Target recruitment is anticipated by the end of Q2 2026, with the potential to extend into Q3 to accommodate patient enrollment from the additional clinical sites.MAVERIC builds on positive Phase II data and is expected to support a New Drug Application with the U.S. FDA.TORONTO, April 28, 2026 /CNW/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, today announced the continued expansion of its pivotal Phase III MAVERIC trial in the United States ("U.S."), with the planned activation of up to seven additional clinical centers. Patient enrollment in MAVERIC surpassed the 50% threshold in early January and has now reached 75%. Target recruitment is anticipated by the end of Q2 2026, with the potential to extend into Q3 to accommodate patient enrollment from additional clinical sites.







"Broadening the MAVERIC clinical site network reflects the strong interest we have received from leading clinical centers across the United States and underscores the level of investigator conviction in both the therapeutic rationale and the unmet need in recurrent pericarditis," said David Elsley, President and Chief Executive Officer of Cardiol Therapeutics. "The participation of multiple premier cardiovascular research institutions gives us confidence that MAVERIC will generate a robust dataset to define the clinical profile of CardiolRx™ and support its potential as a non-immunosuppressive oral, more accessible therapy earlier in the treatment pathway."MAVERIC Phase III TrialMAVERIC is a randomized, double-blind, placebo-controlled pivotal Phase III trial evaluating CardiolRx™ for the prevention of disease recurrence in patients with recurrent pericarditis. The study is designed to enroll approximately 110 patients. MAVERIC was designed with input from the U.S. Food and Drug Administration ("FDA"), with alignment on trial design achieved at an end-of-Phase II meeting in April 2025. The first patient was randomized at Northwestern University in April 2025.Phase II FoundationMAVERIC builds on the clinical evidence established in the Phase II MAvERIC study, which demonstrated that CardiolRx™ produced rapid and sustained reductions in pericarditis pain and inflammation, along with a substantial decrease in recurrent episodes per year. These findings, presented at the American Heart Association Scientific Sessions 2024, provide a compelling clinical and mechanistic foundation for the ongoing pivotal Phase III program and support the potential for CardiolRx™ to address a significant unmet need in recurrent pericarditis.About PericarditisPericarditis refers to inflammation of the pericardium (the membrane or sac that surrounds the heart), which frequently results from a viral infection. Patients may have multiple recurrences following that initial episode, and the primary goal of treatment is recurrence prevention. Symptoms include debilitating chest pain, shortness of breath and fatigue, resulting in physical limitations, reduced quality of life, emergency department visits, and hospitalizations. Significant accumulation of pericardial fluid and scarring can progress to life-threatening constriction of the heart. On an annual basis, the number of patients in the United States experiencing at least one recurrence is estimated at 40,000. Approximately 60% of patients with more than one recurrence suffer for more than two years, and one third remain impacted at five years. Hospitalization due to recurrent pericarditis is typically associated with a 6-8-day stay and cost per stay is estimated to range between $20,000 and $30,000 in the United States.About Cardiol TherapeuticsCardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company's lead small-molecule drug candidate, CardiolRx™, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.The MAVERIC Program is evaluating CardiolRx™ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations. The program comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing pivotal Phase III MAVERIC trial (NCT06708299). The U.S. FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis, including recurrent pericarditis.The ARCHER Program also studied CardiolRx™, specifically in acute myocarditis—an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in individuals under 35 years of age. The program comprises the completed Phase II ARCHER study (NCT05180240), which evaluated the safety, tolerability, and efficacy of CardiolRx™ in this patient population.The Company is also developing CRD-38, a novel, subcutaneously administered drug formulation intended for the treatment of inflammatory heart disease, including heart failure—a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding US$30 billion per year.For more information about Cardiol Therapeutics, please visit cardiolrx.com.Cautionary statement regarding forward-looking information:This news release contains "forward-looking information" within the meaning of applicable securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol believes, expects, or anticipates will, may, could, or might occur in the future are "forward-looking information". Forward looking information contained herein may include, but is not limited to statements regarding the Company's focus on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease; the Company's intended clinical studies and trial activities and timelines associated with such activities, including the Company's plan to complete the Phase III study in recurrent pericarditis with CardiolRx™; the Company's plan to advance the development of CRD-38, a novel subcutaneous formulation intended for the treatment of inflammatory heart disease, including heart failure, including through the initiation of a Phase I clinical program; the Company's belief that results from the ARCHER trial provide compelling clinical proof of concept for CardiolRx™ and strengthen the scientific and clinical rationale for Cardiol's novel therapeutic approach for inflammatory cardiac conditions, including its lead Phase III program in recurrent pericarditis; the Company's expectation that the Phase III MAVERIC trial will reach full enrollment in Q2 2026 with the potential to extend into Q3 to accommodate patient enrollment from the additional clinical sites; the Company's planned activation of up to seven additional clinical centers; the Company's expectation that MAVERIC will support an NDA with the U.S. FDA; the Company's belief that the participation of multiple premier cardiovascular research institutions gives it confidence that MAVERIC will generate a robust dataset to define the clinical profile of CardiolRx™ and support its potential as a non-immunosuppressive oral, more accessible therapy earlier in the treatment pathway; and the Company's ability to address its strategic priorities. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is based on certain assumptions and is also subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward looking information, and are not (and should not be considered to be) guarantees of future performance. These risks and uncertainties and other factors include the risks and uncertainties referred to in the Company's Annual Information Form filed with the Canadian securities administrators and U.S. Securities and Exchange Commission on March 31, 2026, available on SEDAR+ at sedarplus.ca and EDGAR at sec.gov, as well as the risks and uncertainties associated with product commercialization and clinical studies. These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information, and such information may not be appropriate for other purposes. Any forward-looking information speaks only as of the date of this press release and, except as may be required by applicable securities laws, Cardiol disclaims any intent or obligation to update or revise such forward-looking information, whether as a result of new information, future events, or results, or otherwise. Investors are cautioned not to rely on these forward-looking statements.



View original content to download multimedia:https://www.prnewswire.com/news-releases/cardiol-therapeutics-expands-us-maveric-phase-iii-trial-network-to-address-growing-interest-in-the-pivotal-program-302755272.htmlSOURCE Cardiol Therapeutics Inc.

Original: Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program

$CRDL - A better understanding of heart failure is opening new opportunities.

David Elsley highlights why targeting inflammation, without suppressing the immune system, sits at the center of Cardiol’s approach.

$CRDL A better understanding of heart failure is opening new opportunities.

David Elsley highlights why targeting inflammation, without suppressing the immune system, sits at the center of Cardiol’s approach. $CRDL pic.twitter.com/RxSCtYzS7T— Cardiol Therapeutics Inc. (@CardiolRx) April 27, 2026

$CRDL More than 64 million people worldwide are living with heart failure. In the United States, that number is projected to grow from 6.7 million today to more than 11 million by 2050. In Canada, 750,000 people are living with the condition and more than 90,000 are newly diagnosed every year.

One in four people will develop heart failure in their lifetime.

With National Heart Failure Awareness Week approaching we took a closer look at what the data shows and what it means. $CRDL
#HFWeek2026 #HFpEF
More than 64 million people worldwide are living with heart failure. In the United States, that number is projected to grow from 6.7 million today to more than 11 million by 2050. In Canada, 750,000 people are living with the condition and more than 90,000 are newly diagnosed…— Cardiol Therapeutics Inc. (@CardiolRx) April 27, 2026

$CRDL MAVERIC is designed as a pivotal Phase III study to support a potential NDA.

President/CEO David Elsley highlights alignment with the FDA on the study’s primary endpoint. $CRDL pic.twitter.com/QxgUlAL4mx— Cardiol Therapeutics Inc. (@CardiolRx) April 24, 2026

$CRDL A non-immunosuppressive approach to treating inflammatory heart disease.

President/CEO David Elsley highlights how Cardiol’s therapies are designed to modulate inflammation while preserving immune function, with potential for both acute and long-term use.

$CRDL A non-immunosuppressive approach to treating inflammatory heart disease.

President/CEO David Elsley highlights how Cardiol’s therapies are designed to modulate inflammation while preserving immune function, with potential for both acute and long-term use. $CRDL pic.twitter.com/09WlTOscMh— Cardiol Therapeutics Inc. (@CardiolRx) April 24, 2026

$CRDL President/CEO David Elsley highlights the strength of the Phase II data, Cardiol’s collaboration with leading centers, and the opportunity ahead for patients living with this condition. $CRDL President/CEO David Elsley highlights the strength of the Phase II data, Cardiol’s collaboration with leading centers, and the opportunity ahead for patients living with this condition. pic.twitter.com/W3V8YruNSz— Cardiol Therapeutics Inc. (@CardiolRx) April 23, 2026

$CRDL Great Interview out! CRDL President/CEO David Elsley joined @TheDeepDive_ca to break down the key inflection points ahead for
@CardiolRx — including a potential NDA filing for recurrent pericarditis patients with high unmet need who currently have few options beyond immunosuppressants.

#Cardiol #Biotech #ClinicalTrials #HeartHealth #CRDL
$CRDL President/CEO David Elsley joined @TheDeepDive_ca to break down the key inflection points ahead for @CardiolRx — including a potential NDA filing for recurrent pericarditis patients with high unmet need who currently have few options beyond immunosuppressants.#Cardiol… pic.twitter.com/BGbqMw91vq— Cardiol Therapeutics Inc. (@CardiolRx) April 22, 2026

$CRDL CardiolRx™ continues to advance as a potential treatment for inflammation-driven heart disease. Thank you
@SECFilingscom
for highlighting our clinical progress, supportive FDA interactions, and why we believe CardiolRx™ is positioned to make a meaningful difference for patients. Read more 👇 https://secfilings.com/news/small-cap-biotech-is-significantly-outperforming-the-market-and-larger-names #CardiolRx #HeartDisease #ClinicalTrials #Biotech

$CRDL @CardiolRx - Treating Heart Disease Behind Sudden Death in Young People | David Elsey
#cardio #biotechnology #médecine #stockmarket #finance @frontpagestocks

$CRDL Phase III MAVERIC in recurrent pericarditis is past 50% enrollment and is expected to reach full enrollment this quarter, with the FDA having sanctioned the study as a pivotal trial to support a new drug application.

ARCHER myocarditis data showed structural improvement and reduced swelling/edema, suggesting CardiolRx may provide a non–immune-suppressing treatment option in a condition that currently has no approved standard of care.

Cardiol is developing CRD-38 as a once-monthly reformulation, holds a broad U.S. patent on CardiolRx/CRD-38 through 2040, and reports a cash runway into the end of 2027 while pursuing licensing partnerships for commercialization.

https://finance.yahoo.com/sectors/healthcare/articles/cardiol-therapeutics-ceo-phase-iii-101539470.html

$CRDL Great interview! CEO David Elsley covers the pivotal Phase III MAVERIC trial for recurrent pericarditis, published Phase II ARCHER myocarditis results, and next-gen drug CRD-38.

$CRDL News Out : Cardiol Therapeutics CEO: Phase III MAVERIC Nears Full Enrollment as CardiolRx Shows Myocarditis Promise https://finance.yahoo.com/sectors/healthcare/articles/cardiol-therapeutics-ceo-phase-iii-101539470.html

🚀 Big updates from Cardiol Therapeutics ($CRDL)!
CEO David Elsley just broke down the company's latest major clinical milestones in a new interview.


Here are the highlights:

✅ Phase III MAVERIC Trial: The pivotal trial for recurrent pericarditis has surpassed 50% enrollment, with full enrollment expected in Q2 2026!
✅ Phase II ARCHER Data: Positive results published showing CardiolRx™ improves the underlying biology of inflammatory heart disease (acute myocarditis).
✅ Pipeline Expansion: Advancing next-generation drug CRD-38 for heart failure.


With $CRDL up over 40% YTD and fully funded through trial completion, they are making serious waves in cardiovascular biotech. 🫀🧬

Read more here: https://finance.yahoo.com/sectors/healthcare/articles/cardiol-therapeutics-ceo-phase-iii-101539470.html

$CRDL Cardiol Therapeutics CEO: Phase III MAVERIC Nears Full Enrollment as CardiolRx Shows Myocarditis Promise https://finance.yahoo.com/sectors/healthcare/articles/cardiol-therapeutics-ceo-phase-iii-101539470.html

#Breaking $CRDL Cardiol Therapeutics: The Heart Drug Story Retail Investors Aren't Talking About...Yet! ($CRDL) Cardiol Therapeutics: The Heart Drug Story Retail Investors Aren't Talking About...Yet! @CardiolRx https://t.co/s5CQ7gYcNF— Barchart (@Barchart) April 14, 2026

$CRDL " The MAVERIC Program is evaluating CardiolRx™ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations. The program comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing pivotal Phase III MAVERIC trial (NCT06708299). The U.S. FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis, including recurrent pericarditis.

$CRDL is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company's lead small-molecule drug candidate, CardiolRx™, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.

$CRDL News: Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart
TMX Newsfile
Tue, April 14, 2026 at 7:27 AM EDT

Toronto, Ontario--(Newsfile Corp. - April 14, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that Cardiol's President and Chief Executive Officer, David Elsley, will participate in a live interview on X with Barchart.com ("Barchart") today at 12:00 p.m. EDT.

Interview Topics:

The ongoing pivotal Phase III MAVERIC trial of CardiolRx™ in recurrent pericarditis

Results from the recently published Phase II ARCHER trial of CardiolRx™ in acute myocarditis

The Company's next generation drug, CRD-38, in development for heart failure

Interview details:

Date: April 14, 2026
Time: 12:00 PM EDT
Platform: X
Host Account on X: @Barchart
Join Live Interview at: x.com/Barchart

After the event, a full recording of the interview will be available on the Company's X channel (@CardiolRx) and Barchart's (@Barchart).

About Cardiol Therapeutics

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company's lead small-molecule drug candidate, CardiolRx™, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.

The MAVERIC Program is evaluating CardiolRx™ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations. The program comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing pivotal Phase III MAVERIC trial (NCT06708299). The U.S. FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis, including recurrent pericarditis.

The ARCHER Program is also studying CardiolRx™, specifically in acute myocarditis—an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in individuals under 35 years of age. The program comprises the completed Phase II ARCHER study (NCT05180240), which evaluated the safety, tolerability, and efficacy of CardiolRx™ in this patient population.

The Company is also developing CRD-38, a novel, subcutaneously administered drug formulation intended for the treatment of inflammatory heart disease, including heart failure—a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding US$30 billion per year.

For more information about Cardiol Therapeutics, please visit cardiolrx.com.

Cautionary statement regarding forward-looking information:
This news release contains "forward-looking information" within the meaning of applicable securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol believes, expects, or anticipates will, may, could, or might occur in the future are "forward-looking information". Forward-looking information contained herein may include, but is not limited to statements regarding the Company's focus on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease; the Company's intended clinical studies and trial activities and timelines associated with such activities, including the Company's plan to complete the Phase III study in recurrent pericarditis with CardiolRx™; the Company's plan to advance the development of CRD-38, a novel subcutaneous formulation intended for the treatment of inflammatory heart disease, including heart failure. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is based on certain assumptions and is also subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, and are not (and should not be considered to be) guarantees of future performance. These risks and uncertainties and other factors include the risks and uncertainties referred to in the Company's Annual Information Form filed with the Canadian securities administrators and U.S. Securities and Exchange Commission on March 31, 2026, available on SEDAR+ at sedarplus.ca and EDGAR at sec.gov, as well as the risks and uncertainties associated with product commercialization and clinical studies. These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information, and such information may not be appropriate for other purposes. Any forward-looking information speaks only as of the date of this press release and, except as may be required by applicable securities laws, Cardiol disclaims any intent or obligation to update or revise such forward-looking information, whether as a result of new information, future events, or results, or otherwise. Investors are cautioned not to rely on these forward-looking statements.

For further information, please contact:
Investor.relations@cardiolrx.comhttps://api.newsfilecorp.com/redirect/XEKqqtM0aQ

🚨 $CRDL Cardiol Therapeutics President & CEO David Elsley is going LIVE today at 12:00 PM EDT in an exclusive interview with @Barchart on X! 🎙️ https://newsfilecorp.com/release/292336

Expect major updates on their clinical pipeline momentum, including:
✅ The pivotal Phase III MAVERIC trial for recurrent pericarditis
✅ Newly published Phase II ARCHER results in acute myocarditis
✅ The next-gen drug CRD-38 in development for heart failure

Set your reminders and tune in at http://x.com/Barchart! ⏳📈

#StockOnHighAlert #FrontPageStocks #CRDL #Biotech #Investing #CardiolRx #WallStreet

Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with BarchartApril 14, 2026 7:27 AM
NewsfileToronto, Ontario--(Newsfile Corp. - April 14, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that Cardiol's President and Chief Executive Officer, David Elsley, will participate in a live interview on X with Barchart.com ("Barchart") today at 12:00 p.m. EDT.Interview Topics:The ongoing pivotal Phase III MAVERIC trial of CardiolRx™ in recurrent pericarditisResults from the recently published Phase II ARCHER trial of CardiolRx™ in acute myocarditisThe Company's next generation drug, CRD-38, in development for heart failureInterview details:Date: April 14, 2026
Time: 12:00 PM EDT
Platform: X
Host Account on X: @Barchart
Join Live Interview at: x.com/BarchartAfter the event, a full recording of the interview will be available on the Company's X channel (@CardiolRx) and Barchart's (@Barchart).About Cardiol TherapeuticsCardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company's lead small-molecule drug candidate, CardiolRx™, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.The MAVERIC Program is evaluating CardiolRx™ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations. The program comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing pivotal Phase III MAVERIC trial (NCT06708299). The U.S. FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis, including recurrent pericarditis.The ARCHER Program is also studying CardiolRx™, specifically in acute myocarditis—an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in individuals under 35 years of age. The program comprises the completed Phase II ARCHER study (NCT05180240), which evaluated the safety, tolerability, and efficacy of CardiolRx™ in this patient population.The Company is also developing CRD-38, a novel, subcutaneously administered drug formulation intended for the treatment of inflammatory heart disease, including heart failure—a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding US$30 billion per year.For more information about Cardiol Therapeutics, please visit cardiolrx.com.Cautionary statement regarding forward-looking information:
This news release contains "forward-looking information" within the meaning of applicable securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol believes, expects, or anticipates will, may, could, or might occur in the future are "forward-looking information". Forward-looking information contained herein may include, but is not limited to statements regarding the Company's focus on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease; the Company's intended clinical studies and trial activities and timelines associated with such activities, including the Company's plan to complete the Phase III study in recurrent pericarditis with CardiolRx™; the Company's plan to advance the development of CRD-38, a novel subcutaneous formulation intended for the treatment of inflammatory heart disease, including heart failure. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is based on certain assumptions and is also subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, and are not (and should not be considered to be) guarantees of future performance. These risks and uncertainties and other factors include the risks and uncertainties referred to in the Company's Annual Information Form filed with the Canadian securities administrators and U.S. Securities and Exchange Commission on March 31, 2026, available on SEDAR+ at sedarplus.ca and EDGAR at sec.gov, as well as the risks and uncertainties associated with product commercialization and clinical studies. These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information, and such information may not be appropriate for other purposes. Any forward-looking information speaks only as of the date of this press release and, except as may be required by applicable securities laws, Cardiol disclaims any intent or obligation to update or revise such forward-looking information, whether as a result of new information, future events, or results, or otherwise. Investors are cautioned not to rely on these forward-looking statements.For further information, please contact:
Investor.relations@cardiolrx.comTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/292336
Original: Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart

$CRDL Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, today announced its year-end 2025 update on operations following the filing of its audited Financial Statements and Management's Discussion and Analysis for the year ended December 31, 2025. Both are available under the Company's profile on EDGAR at www.sec.gov, on SEDAR+ at sedarplus.ca, and on the Company's website at cardiolrx.com.

$CRDL Cardiol Therapeutics Inc. is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease.
@CardiolRx
https://cardiolrx.com/about-us/#section=overview

🚨 $CRDL BREAKING MOMENTUM – Cardiol Therapeutics Fully Funded for Pivotal Phase III Heart Trial! 🔥


Cardiol Therapeutics ($CRDL) just highlighted major 2025 progress in its Year-End Operations Update:
https://finance.yahoo.com/sectors/healthcare/articles/cardiol-therapeutics-fiscal-2025-loss-182419254.html

🔹MAVERIC Phase III trial for recurrent pericarditis now >50% enrolled — full enrollment targeted for Q2 2026
🔹Positive Phase II ARCHER results showed significant reduction in left ventricular mass
🔹CRD-38 oral formulation advancing toward IND/Phase I
🔹New U.S. patent allowance extending protection to 2040
🔹Raised ~$31M in recent financings — now fully funded through MAVERIC completion and into Q4 2027

Canaccord Genuity recently reaffirmed Buy rating with $8.00 price target — that’s over 500% upside from current levels around $1.29–$1.40.

Late-stage biotech play targeting serious inflammatory heart diseases with strong clinical momentum and solid cash runway.

Who’s watching $CRDL as this Phase III trial advances?

Drop 🔥 if you’re bullish on this cardiac innovation story!

#CRDL #CardiolTherapeutics #Biotech #HeartDisease #Stocks

Cardiol Therapeutics Announces Year-End 2025 Update on OperationsApril 1, 2026 7:27 AM
NewsfileInitiated pivotal Phase III MAVERIC trial of CardiolRx™ in recurrent pericarditis and surpassed 50% patient enrollment, with full enrollment expected in Q2 2026.Reported positive Phase II ARCHER data showing CardiolRx™ significantly reduced left ventricular mass in patients with acute myocarditis; results published in ESC Heart Failure.Advanced CRD-38 program, a novel next generation drug intended for use in heart failure and other inflammatory heart diseases, to support an Investigational New Drug ("IND") Application and the initiation of Phase I clinical development.Received U.S. patent allowance broadly protecting CardiolRx™ and CRD-38 for use in the treatment or prevention of an extensive range of cardiac conditions through late 2040.Strengthened Board of Directors with election of Dr. Timothy Garnett, former Chief Medical Officer of Eli Lilly and Company.Raised aggregate gross proceeds of $31 million providing a cash runway into Q4 2027.Toronto, Ontario--(Newsfile Corp. - April 1, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, today announced its year-end 2025 update on operations following the filing of its audited Financial Statements and Management's Discussion and Analysis for the year ended December 31, 2025. Both are available under the Company's profile on EDGAR at www.sec.gov, on SEDAR+ at sedarplus.ca, and on the Company's website at cardiolrx.com."2025 was a pivotal year of clinical execution and strategic advancement for Cardiol. We initiated our Phase III MAVERIC trial in recurrent pericarditis, reported positive Phase II ARCHER data demonstrating that CardiolRx™ improves the underlying biology of inflammatory heart disease and reduces inflammation-driven structural damage, and strengthened our balance sheet to support key value-inflection milestones," said David Elsley, President and Chief Executive Officer of Cardiol Therapeutics."We are now fully funded through completion of the MAVERIC trial, which is designed to support a New Drug Application submission for CardiolRx™ in the prevention of recurrent pericarditis-an expanding market with a significant unmet need for a safe, accessible, non-immunosuppressive oral therapy. In parallel, the positive ARCHER results-our second successful Phase II study in inflammatory heart disease-along with continued expansion of our patent portfolio in the United States and advancement of CRD-38 toward IND submission, further strengthen our product pipeline. We thank our clinical collaborators and the patients whose participation has enabled this progress."Key Highlights:Pivotal Phase III MAVERIC Trial in Recurrent PericarditisMAVERIC is a randomized, double-blind, placebo-controlled Phase III trial evaluating CardiolRx™ for the prevention of disease recurrence in patients with recurrent pericarditis. The study is designed to enroll approximately 110 patients across 25 clinical sites predominantly in the United States. Subject to positive outcomes, MAVERIC is expected to support a New Drug Application ("NDA") with the U.S. FDA.In April 2025, we successfully achieved regulatory alignment and trial design validation with the U.S. FDA, which supports the potential of the MAVERIC study to enable an NDA.In April 2025, the first patient was randomized at Northwestern University in Chicago. Throughout 2025, clinical trial infrastructure was established and enrollment accelerated across leading cardiovascular research centers in the United States.The MAVERIC Phase III trial builds on positive results from the Phase II MAvERIC study, where patients treated with CardiolRx™ experienced rapid, sustained reductions in pericarditis pain and inflammation, along with a substantial reduction in pericarditis episodes per year. These findings were presented at the 2024 American Heart Association Scientific Sessions.MAVERIC secured strong engagement from leading academic and clinical investigators, establishing a high-quality site network and positioning the trial for robust data generation and efficient enrollment timelines."The pace of enrollment in MAVERIC reflects strong investigator confidence in CardiolRx™ and highlights the significant unmet need in recurrent pericarditis," said Dr. Andrew Hamer, Chief Medical Officer and Head of Research & Development. "Current treatment pathways often progress from conventional anti-inflammatories to corticosteroids and ultimately to costly injectable biologics that suppress the immune system. CardiolRx™ is being evaluated as an oral, accessible, non-immunosuppressive therapy that could be used prior to corticosteroids and biologics, with the potential to address the needs of a broader patient population."Phase II ARCHER Trial in Acute MyocarditisARCHER was a randomized, double-blind, placebo-controlled Phase II trial of CardiolRx™ in 109 patients with acute myocarditis at 34 sites across five countries. There are no FDA-approved therapies for myocarditis.In August 2025, the Company reported topline results from ARCHER. CardiolRx™ produced a significant reduction in left ventricular ("LV") mass (-9.2g; p=0.0117) and was shown to improve multiple pre-specified cardiac magnetic resonance imaging ("CMR") endpoints following 12 weeks of treatment, providing the first clinical evidence that CardiolRx™ can improve cardiac structure, heart size, recovery, and function in patients with inflammatory heart disease. The magnitude of LV mass reduction observed in ARCHER is similar to that achieved with several commonly prescribed blockbuster drugs for heart failure, obesity, and hypertension-treatments proven to improve long-term survival and reduce major cardiac events.In November 2025, new and comprehensive data from ARCHER were presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases in Trieste, Italy. The presentation provided additional CMR endpoint data indicating that the meaningful structural improvement in the heart was the result of recovery from inflammation-driven edema. Consistent with prior clinical studies in inflammatory heart disease, CardiolRx™ was shown to be safe and well tolerated.Subsequent to year-end, in February 2026, the full ARCHER study results were published in ESC Heart Failure, a leading journal of the European Society of Cardiology, providing broader peer-reviewed dissemination of the clinical evidence to the international cardiology community.The ARCHER results provide additional support for the ongoing MAVERIC trial in recurrent pericarditis. Myocarditis and pericarditis are inflammatory diseases of the myocardium and pericardium, respectively, and are recognized to fall within the spectrum of inflammatory myopericardial syndrome, an umbrella term describing the potential myocarditis-pericarditis overlap: similar causes, anatomical contiguous structures, and mixed forms with possible reciprocal involvement, such as myopericarditis and perimyocarditis."The results of ARCHER are the first that I am aware of to demonstrate improvements in key measures of cardiac structure and remodeling in patients with myocarditis," said Dr. Dennis M. McNamara, Professor of Medicine at the University of Pittsburgh, Director of the Center for Heart Failure Research at the University of Pittsburgh Medical Center, and Chair of the ARCHER trial. "The results constitute exciting clinical proof of concept that supports advancing the clinical development of this novel therapeutic approach for inflammatory cardiac conditions, including heart failure."Advancing CRD-38 into Phase I Clinical DevelopmentCRD-38 is the Company's novel next generation drug in development for inflammatory heart diseases including heart failure, a leading cause of hospitalization worldwide with five-year mortality exceeding 75% in hospitalized patients. Whereas the role of inflammation in heart failure is well recognized, there are no specifically targeted therapies currently approved for clinical practice that address the underlying inflammation and fibrosis that drive disease processes.Throughout 2025, the Company advanced IND-enabling studies and conducted activities necessary to support an IND application with the U.S. FDA and the initiation of a Phase I clinical program. This progress included formulation optimization, as well as the conduct of pharmacokinetic and toxicology studies.In February 2025, Cardiol announced the publication of research in the Journal of the American College of Cardiology: Basic to Translational Science demonstrating that subcutaneously administered cannabidiol provides cardioprotection in a heart failure model by improving cardiac function and reducing hypertrophy, remodelling, inflammation, and cell death through preservation of mitochondrial function.Intellectual Property ExpansionIn November 2025, Cardiol received a U.S. patent allowance broadly protecting its heart drugs, including CardiolRx™ and CRD-38, for use in the treatment or prevention of an extensive range of cardiac conditions, including heart failure, myocarditis, acute pericarditis, inflammatory cardiomyopathy, cardiac toxicity from anti-cancer therapies, and atherosclerosis, to October 2040. The patent allowance covers new areas of heart disease, including those identified for potential research expansion based on the ARCHER findings, adding extensive intellectual property protection to the Company's product portfolio.Board of DirectorsIn May 2025, Dr. Timothy J. Garnett was elected to the Board of Directors. Dr. Garnett served as Chief Medical Officer of Eli Lilly and Company from 2008 to 2021, where he led the development and global commercial launch of multiple therapeutics across a 20-year tenure. His regulatory and commercialization experience strengthens the Board as the Company approaches potential registrational milestones.Strengthened Balance SheetIn October 2025, Cardiol completed a private placement for total proceeds of approximately $16 million. Subsequent to year-end, in January 2026, the Company closed a bought deal financing with full exercise of the over-allotment option for gross proceeds of $14.85 million. The combined financings provide a cash runway into Q4 2027.OutlookThe Company's strategic priorities include the following:Complete full patient enrollment in the Phase III MAVERIC trial to enable timely progression toward topline data reporting and a potential NDA submission.Initiate clinical development of CRD-38 to establish a second major value-driver for the treatment of heart disease.Collaborate with KOLs in inflammatory heart disease to evaluate additional high-value rare disease programs, leveraging the ARCHER results.Advance discussions and negotiations with prospective strategic partners to provide global market access and maximize the commercial potential of the Company's drug candidates.Continue to broaden awareness of the Company's groundbreaking research through presentations at major cardiology conferences and publications in peer-reviewed journals."We enter this next phase of development with a clearly defined path forward: pivotal data in recurrent pericarditis, a growing body of published research supporting our programs, and the financial resources to execute," added David Elsley. "The strong engagement of leading cardiovascular investigators actively enrolling patients in MAVERIC and the robust clinical data recently generated from the ARCHER trial, reinforce our conviction that we are well positioned to deliver meaningful therapies for inflammatory heart disease".About Cardiol TherapeuticsCardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company's lead small-molecule drug candidate, CardiolRx™, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.The MAVERIC Program is evaluating CardiolRx™ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations. The program comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing pivotal Phase III MAVERIC trial (NCT06708299). The U.S. FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis, including recurrent pericarditis.The ARCHER Program is also studying CardiolRx™, specifically in acute myocarditis-an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in individuals under 35 years of age. The program comprises the completed Phase II ARCHER study (NCT05180240), which evaluated the safety, tolerability, and efficacy of CardiolRx™ in this patient population.The Company is also developing CRD-38, a novel, subcutaneously administered drug formulation intended for the treatment of inflammatory heart disease, including heart failure-a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding US$30 billion per year.For more information about Cardiol Therapeutics, please visit cardiolrx.com.Cautionary statement regarding forward-looking information:
This news release contains "forward-looking information" within the meaning of applicable securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol believes, expects, or anticipates will, may, could, or might occur in the future are "forward-looking information". Forward-looking information contained herein may include, but is not limited to statements regarding the Company's focus on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease; the Company's intended clinical studies and trial activities and timelines associated with such activities, including the Company's plan to complete the Phase III study in recurrent pericarditis with CardiolRx™; the Company's plan to advance the development of CRD-38, a novel subcutaneous formulation intended for the treatment of inflammatory heart disease, including heart failure, including through the initiation of a Phase I clinical program; the Company's belief that results from the ARCHER trial provide compelling clinical proof of concept for CardiolRx™ and strengthen the scientific and clinical rationale for Cardiol's novel therapeutic approach for inflammatory cardiac conditions, including its lead Phase III program in recurrent pericarditis; the Company's expectation that the Phase III MAVERIC trial will reach full enrollment in Q2 2026; the Company's expectation that MAVERIC will support an NDA with the U.S. FDA.; and the Company's ability to address its strategic priorities. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is based on certain assumptions and is also subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, and are not (and should not be considered to be) guarantees of future performance. These risks and uncertainties and other factors include the risks and uncertainties referred to in the Company's Annual Information Form filed with the Canadian securities administrators and U.S. Securities and Exchange Commission on March 31, 2026, available on SEDAR+ at sedarplus.ca and EDGAR at sec.gov, as well as the risks and uncertainties associated with product commercialization and clinical studies. These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information, and such information may not be appropriate for other purposes. Any forward-looking information speaks only as of the date of this press release and, except as may be required by applicable securities laws, Cardiol disclaims any intent or obligation to update or revise such forward-looking information, whether as a result of new information, future events, or results, or otherwise. Investors are cautioned not to rely on these forward-looking statements.For further information, please contact:
Investor.relations@cardiolrx.comTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/290813
Original: Cardiol Therapeutics Announces Year-End 2025 Update on Operations

Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care ConferenceFebruary 25, 2026 7:27 AM
NewsfileToronto, Ontario--(Newsfile Corp. - February 25, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate at the upcoming TD Cowen 46th Annual Health Care Conference in Boston, MA. Members of management will present on March 4, 2026, at 10:30 a.m. EST.A live webcast of the Company's presentation, as well as a webcast replay will be available under "Events & Presentations" in the Investors section of the Cardiol website (www.cardiolrx.com/investors/events-presentations/).About Cardiol TherapeuticsCardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company's lead small-molecule drug candidate, CardiolRx™, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.The MAVERIC Program is evaluating CardiolRx™ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations. The program comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing pivotal Phase III MAVERIC trial (NCT06708299). The U.S. FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis, including recurrent pericarditis.The ARCHER Program is also studying CardiolRx™, specifically in acute myocarditis-an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in individuals under 35 years of age. The program comprises the completed Phase II ARCHER study (NCT05180240), which evaluated the safety, tolerability, and efficacy of CardiolRx™ in this patient population.The Company is also developing CRD-38, a novel, subcutaneously administered drug formulation intended for the treatment of inflammatory heart disease, including heart failure-a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding US$30 billion per year.For more information about Cardiol Therapeutics, please visit cardiolrx.com.Cautionary statement regarding forward-looking information:This news release contains "forward-looking information" within the meaning of applicable securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol believes, expects, or anticipates will, may, could, or might occur in the future are "forward-looking information". Forward-looking information contained herein may include, but is not limited to statements regarding the Company's focus on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, the Company's intended clinical studies and trial activities and timelines associated with such activities, including the Company's plan to complete the Phase III study in recurrent pericarditis with CardiolRx™, and the Company's plan to advance the development of CRD-38, a novel subcutaneous formulation intended for the treatment of inflammatory heart disease, including heart failure, including through the initiation of the first-in-human clinical evaluation. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is based on certain assumptions and is also subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, and are not (and should not be considered to be) guarantees of future performance. These risks and uncertainties and other factors include the risks and uncertainties referred to in the Company's Annual Information Form filed with the Canadian securities administrators and U.S. Securities and Exchange Commission on March 31, 2025, available on SEDAR+ at sedarplus.ca and EDGAR at sec.gov, as well as the risks and uncertainties associated with product commercialization and clinical studies. These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information, and such information may not be appropriate for other purposes. Any forward-looking information speaks only as of the date of this press release and, except as may be required by applicable securities laws, Cardiol disclaims any intent or obligation to update or revise such forward-looking information, whether as a result of new information, future events, or results, or otherwise. Investors are cautioned not to rely on these forward-looking statements.For further information, please contact:
Investor.relations@cardiolrx.comTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/285225
Original: Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference

Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart FailureFebruary 10, 2026 7:27 AM
NewsfileToronto, Ontario--(Newsfile Corp. - February 10, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, today announced the publication of results from its Phase II ARCHER study in ESC Heart Failure, a journal of the European Society of Cardiology.The peer-reviewed article reports results from a randomized, double-blind, placebo-controlled trial evaluating CardiolRx™, Cardiol's lead oral drug candidate, in 109 patients with acute myocarditis using advanced cardiac magnetic resonance (CMR) imaging measures of myocardial inflammation and remodelling.In the study, treatment with CardiolRx™ produced a significant reduction in left ventricular mass versus placebo (-9.2 g; p=0.0117), along with a decrease in left atrial remodelling, and favorable trends across multiple markers of myocardial inflammation. CardiolRx was also shown to be safe and well tolerated. Reduction in left ventricular mass is widely considered consistent with decreased myocardial edema and inflammatory burden in myocarditis and improved clinical outcomes.The biological signals observed in ARCHER are directly relevant to Cardiol's ongoing pivotal Phase III MAVERIC trial in recurrent pericarditis. Myocarditis and pericarditis are inflammatory diseases of the myocardium and pericardium, respectively, and are recognized to fall within the spectrum of inflammatory myopericardial syndrome, an umbrella term describing the potential myocarditis-pericarditis overlap: similar causes, anatomical contiguous structures, and mixed forms with possible reciprocal involvement, such as myopericarditis and perimyocarditis."This publication marks an important moment in the broader dissemination of CardiolRx's therapeutic potential," said David Elsley, President and Chief Executive Officer of Cardiol Therapeutics. "ARCHER provides additional compelling clinical evidence that CardiolRx impacts the underlying biology of inflammatory heart disease and reduces inflammation-driven structural damage in the heart, increasing our confidence in MAVERIC, which is focused on delivering meaningful outcomes for patients with recurrent pericarditis."The full paper is available at:
https://academic.oup.com/eschf/advance-article/doi/10.1093/eschf/xvaf034/8427108 About Cardiol TherapeuticsCardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company's lead small-molecule drug candidate, CardiolRx™, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.The MAVERIC Program is evaluating CardiolRx™ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations. The program comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing pivotal Phase III MAVERIC trial (NCT06708299). The U.S. FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis, including recurrent pericarditis.The ARCHER Program is also studying CardiolRx™, specifically in acute myocarditis-an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in individuals under 35 years of age. The program comprises the completed Phase II ARCHER study (NCT05180240), which evaluated the safety, tolerability, and efficacy of CardiolRx™ in this patient population.The Company is also developing CRD-38, a novel, subcutaneously administered drug formulation intended for the treatment of inflammatory heart disease, including heart failure-a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding US$30 billion per year.For more information about Cardiol Therapeutics, please visit cardiolrx.com.Cautionary statement regarding forward-looking information:This news release contains "forward-looking information" within the meaning of applicable securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol believes, expects, or anticipates will, may, could, or might occur in the future are "forward-looking information". Forward looking information contained herein may include, but is not limited to statements regarding the Company's focus on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, the Company's intended clinical studies and trial activities and timelines associated with such activities, including the Company's plan to complete the Phase III study in recurrent pericarditis with CardiolRx™, the Company's plan to advance the development of CRD-38, a novel subcutaneous formulation intended for the treatment of inflammatory heart disease, including heart failure, including through the initiation of the first-in-human clinical evaluation, and the Company's belief that results from the ARCHER trial provide compelling clinical proof of concept for CardiolRx™, strengthen the scientific and clinical rationale for Cardiol's lead Phase III program in recurrent pericarditis. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is based on certain assumptions and is also subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward looking information, and are not (and should not be considered to be) guarantees of future performance. These risks and uncertainties and other factors include the risks and uncertainties referred to in the Company's Annual Information Form filed with the Canadian securities administrators and U.S. Securities and Exchange Commission on March 31, 2025, available on SEDAR+ at sedarplus.ca and EDGAR at sec.gov, as well as the risks and uncertainties associated with product commercialization and clinical studies. These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information, and such information may not be appropriate for other purposes. Any forward-looking information speaks only as of the date of this press release and, except as may be required by applicable securities laws, Cardiol disclaims any intent or obligation to update or revise such forward-looking information, whether as a result of new information, future events, or results, or otherwise. Investors are cautioned not to rely on these forward-looking statements.For further information, please contact:
Investor.relations@cardiolrx.comTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/283346
Original: Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure

(j) Checkbox checked A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)

Tejara Capital Limited is an authorised by FCA in UK as a fund manager and it manages the fund Trefoil Select Funds SPC-Stylus SP, this is registered in Cayman
Item 4. Ownership
(a) Amount beneficially owned:

5,130,122 plus 1,250,000 warrants
(b) Percent of class:

5.2 %
https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&ref=319524907&type=HTML&symbol=CRDL&cdn=c2c52a473603aae3fce49f2bdd9e8e88&companyName=Cardiol+Therapeutics+Inc.&formType=SCHEDULE+13G&formDescription=Statement+of+acquisition+of+beneficial+ownership+by+individuals&dateFiled=2025-10-23

Sure 12, have another beer but good buy - hammer looks good for next advance
Good luck.

She's got a big mailbox, that she puts up front
Garbage in, garbage out, she's getting what she wants..
CRDL$

Lol, been a long time. What a great stalk!. Goes up and down like Jack.
Bought bottom (again ;) and bullish as always. Why be negative ;).
[.. and no I do not want you to buy my shares.. yet ;]
CRDL$

https://www.youtube.com/watch?v=sY8aFSY2zv4&ab_channel=LexFridman

Boom outta da startin' gates..

Are we there yet, gettin' itchy finger?.

https://www.pinterest.ca/pin/788411478508269766/

Ughhh

Looks terrible. Wait until bottom is confirmed.

Gotta start somewhere!, lol..

edit

Cuz of my poor memory - I have to take a starter
To know what I own ;).